New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study

Table 4 Univariate analysis of risk factors for CNS relapse in the R-CHOP set

Variable	Total (cases)	CNS relapse [cases (%)]	P
Stage			0.049
I or II	217	4 (1.8)
III or IV	159	10 (6.3)
IPI			0.017
0–2	289	7 (2.4)
3–5	87	7 (8.0)
Number of involved extranodal sites^a			0.004
≤1	303	7 (2.3)
>1	71	7 (9.9)
Bone marrow involvement			0.004
No	360	11 (3.1)
Yes	16	3 (18.8)
Bone involvement			0.001
No	335	9 (2.7)
Yes	41	5 (12.2)
Renal involvement			<0.001
No	360	10 (2.8)
Yes	16	4 (25.0)
Testicular involvement			0.043
No	368	13 (3.5)
Yes	8	1 (12.5)
LC			0.081
<1.3 × 10⁹	132	12 (9.1)
≥1.3 × 10⁹	244	2 (0.8)
ALP			0.019
≤110 U/L	341	10 (2.9)
>110 U/L	35	4 (11.4)
HDL^b			0.028
<0.78 mmol/L	64	10 (15.6)
≥0.78 mmol/L	307	4 (1.3)
IT chemotherapy prophylaxis^c			0.083
No	329	10 (3.0)
Yes	44	4 (9.1)

ISSN: 2523-3548